

Contents

Acknowledgements	xi
Preface	xiii
Abbreviations	xvii
1 Introduction	1
1.1 The global burden of CNS disease	2
1.2 Assessment of the global burden of disease	3
1.3 The prevalence of CNS disorders	5
1.4 Disability due to CNS disorders	5
1.5 Economic Costs	8
1.6 Concluding comments	11
References	11
2 An overview of the major CNS disorders	13
2.1 Introduction	13
2.2 Overview of psychiatric disorders	17
2.3 Overview of neurological/neurodegenerative disorders	31
2.4 Concluding comments	37
References	38
3 Neurobiological substrates of CNS disorders	43
3.1 Introduction	43
3.2 Brief introduction to the principles of chemical neurotransmission	44
3.3 Stages of chemical neurotransmission	47
3.4 Approaches to investigating CNS alterations in CNS disorders	50
3.5 Evidence for a neurobiological rationale for CNS disorders	53
3.6 Concluding comments	61
References	62
4 Current pharmacological targets	65
4.1 Introduction	65
4.2 Pharmacological treatments for depression	67
4.3 Pharmacological treatments for schizophrenia	71

4.4	Pharmacological treatments for anxiety disorders	75
4.5	Pharmacological treatments for epilepsy	77
4.6	Pharmacological treatments for Parkinson's disease	80
4.7	Pharmacological treatments for Alzheimer's disease	82
4.8	Concluding comments	83
	References	84
5	Premarketing efficacy evaluation	87
5.1	Introduction	87
5.2	Target identification	90
5.3	Lead optimisation	91
5.4	Target validation in animal models	97
5.5	The use of genetically modified animals in CNS drug development	100
5.6	A selection of animal models of psychiatric disease	101
5.7	A selection of animal models of neurodegenerative disease	108
5.8	Which models to choose	111
5.9	Clinical trials that evaluate drug efficacy	112
5.10	Specific drug profiles	120
	References	121
6	Pharmacokinetic considerations: Absorption, distribution, metabolism and elimination	127
6.1	Introduction	127
6.2	What are the 'ideal' pharmacokinetic properties for a CNS drug?	129
6.3	Absorption	131
6.4	Distribution	141
6.5	Metabolism	150
6.6	Elimination	158
6.7	Measurement of drug concentrations	160
6.8	Factors that affect pharmacokinetics	161
6.9	Allometric scaling	163
6.10	Microdosing (Phase 0) Studies	163
6.11	Dose prediction and therapeutic drug monitoring	164
6.12	Stereoselectivity of metabolism of drugs	164
6.13	Specific drug profiles	165
6.14	Concluding comments	166
	References	166
7	Safety concerns	173
7.1	Introduction	173
7.2	Postmarketing surveillance	174
7.3	Acute poisoning	175
7.4	Quantification of the relative risk of fatalities from CNS drugs	176
7.5	Adverse drug reactions (ADRs)	182

7.6	Specific types of toxicity encountered with psychotropic drugs	183
7.7	Safety concerns following long-term administration of CNS Drugs	185
7.8	Polypharmacy	199
7.9	Specific drug profiles	201
7.10	Concluding comments	203
	References	204
	Websites	210
8	Preclinical and clinical safety evaluation	211
8.1	Introduction	211
8.2	Preclinical exploratory toxicology and safety pharmacology evaluations	215
8.3	Primary and secondary pharmacology	216
8.4	Safety pharmacology	220
8.5	Toxicology studies required for regulatory purposes	224
8.6	Clinical Studies	238
8.7	Specific drug profiles	239
8.8	Concluding comments	240
	References	241
	Websites	244
9	CNS drug targets in development and future perspectives	245
9.1	Introduction	245
9.2	How much does it cost to develop a drug?	247
9.3	Clinical drug development times	248
9.4	Harmonisation between regulatory agencies	248
9.5	Development of biomarkers for clinical efficacy	249
9.6	Quality of life issues	255
9.7	Cost-effectiveness of novel treatments	257
9.8	Patient advocacy groups	258
9.9	Novel targets for CNS disorders	259
9.10	Targets in selected CNS disorders	261
9.11	Targeting of signalling pathways	270
9.12	Cardiovascular drugs in Alzheimer's disease	273
9.13	Modifying oxidative stress and inflammatory responses	274
9.14	Targeting of the amyloid- β protein in Alzheimer's disease	276
9.15	Concluding comments	278
	References	279
	Appendices	287
	Index	295